NCT04896697
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are eligible for part 1A, but only patients with triple negative breast cancer (TNBC) are eligible for Part 1B; These TNBC patients must have progressed on or after prior anti-PD-1 or anti-PD-L1 therapy
Exclusions: Patients who received prior treatment with anti-CTL-4 therapy
https://ClinicalTrials.gov/show/NCT04896697